부산대학교 도서관

The present cross-sectional study evaluated the status and relationship of interleukin-6, a platelet growth factor, with platelet counts, viral load, CD4 counts, and antiretroviral treatment in 75 HIV-infected subjects with thrombocytopenia and 50 gender-, race-, age- and antiretroviral treatment-matched controls without thrombocytopenia. Mean IL-6 production was significantly higher in thrombocytopenic participants (13?432?±?8596) than in non-thrombocytopenic subjects (12?859?±?3538?pg/10 5 Lym). Univariate analyses indicated, however, that thrombocytopenic patients were more likely to have <3000?pg of IL-6 than non-thrombocytopenic patients (OR?=?7 95% CI 1.3–12; P ?=?0.01). For additional analyses, participants were dichotomized above and below 3000?pg of IL-6. Despite similar age, gender, drug use and antiretroviral treatment, thrombocytopenic participants had lower CD4 counts (186.5?±?149 vs. 401?±?286, P ?=?0.005) than non-thrombocytopenic subjects. Thrombocytopenic participants with elevated IL-6, with or without HAART, were more likely to have higher HIV-replication (496?273?±?210?416; 34?656?±?25?332) than thrombocytopenic individuals with low IL-6 levels (105?332?±?42?699; 19?015?±?14?296 P ?=?0.05). Non-thrombocytopenic patients with high IL-6 levels exhibited the highest CD4s (466.7?±?333) and the lowest viral burden (63?094?±?53?300) of the groups. Two distinct categories of HIV-associated thrombocytopenia exist: one accompanied by low IL-6, and another with compensatory elevations of IL-6. In thrombocytopenic individuals, the latter was associated with the poorest immunological and virological responses. [ABSTRACT FROM AUTHOR]